

**Patent 7,320,976**

**PATENT**

**IN UNITED STATES PATENT AND TRADEMARK OFFICE**

Patent No.: 7,320,976

Docket No: 17501CON1 (AP)

Issue Date: January 22, 2008

Patentee: Chin-Ming Chang et al.

Serial No.: 10/685941

Confirmation No.: 7685

Title COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL  
OPHTHALMIC USE

**REQUEST FOR CERTIFICATION OF CORRECTION**

Attn: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text of the Certificate in the suggested form are enclosed.

Pursuant to 1.20(a), the examiner is authorized to charge the Certificate of Correction fee of \$100.00 to the Deposit Account No. 010885.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

The Examiner is authorized to charge any additional fees or credit overpayment to Deposit Account No. 010885.

Respectfully submitted,

Date: February 7, 2008

By: /Brent A. Johnson/  
Brent A. Johnson  
Reg. No.: 51,851  
Agent of Record

Please send all inquiries and  
correspondence to:  
Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714/246-4348  
Facsimile: 714/246-4249

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chin-Ming Chang et al.

Examiner: Kwon, Brian Yong S

Patent No.: 7,320,976

Group Art Unit: 1614

Issue Date: January 22, 2008

Docket No: 17501CON1 (AP)

Serial No.: 10/685,941

Confirmation No.: 7685

Title: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE

Attn: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the attached:

- ☒ Authorization to charge the Certificate of Correction fee of \$100.00 to the Deposit Account No. 010885.
- ☒ Request for Certificate of Correction.
- ☒ Certificate of Correction Form - PTO-1050

**Please charge any additional fees or credit overpayment to Deposit Account No. 010885.**

Respectfully submitted,

Date: February 7, 2008

By: /Brent A. Johnson/  
Brent A. Johnson  
Reg. No.: 51,851  
Agent of Record

Please send all inquiries and  
correspondence to:  
Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714/246-4348  
Facsimile: 714/246-4249

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,320,976

DATED : January 22, 2008

INVENTOR(S) : Chang et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in field (56), under "Other Publications", in column 1, line 4, delete "comcomitant" and insert - - concomitant - -, therefor.

On the face page, in field (56), under "Other Publications", in column 2, line 27, delete "trated" and insert - - treated - -, therefor.

On the face page, in field (56), under "Other Publications", in column 2, line 32, delete "vo." and insert - - vol. - -, therefor.

On the face page, in field (57), under "Abstract", in column 2, lines 1-2, delete "brimondine" and insert - - brimonidine - -, therefor.

In column 1, line 64, delete "(2imi-" and insert - - (2-imi- - -, therefor.

In column 4, line 5, after "timolol)" insert - - . - -.

In column 4, line 11, delete "benzalalkonium" and insert - - benzalkonium - -, therefor.

In column 4, line 48, after "control" insert - - . - -.

In column 4, line 51, after "site" insert - - . - -.

In column 4, line 53, after "12" insert - - . - -.

In column 5, line 43, after "investigator" insert - - . - -.

In column 8, line 23, after "conjunctival" delete "15".

In column 9, line 8, delete "[p=0.0061]" and insert - - [p=0.006] - -, therefor.

MAILING ADDRESS OF SENDER:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. 7,320,976

Atty Docket No: 17501CON1 (AP)

